scholarly journals The Use of a Synthetic Cannabinoid in the Management of Treatment-Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

2009 ◽  
Vol 15 (1) ◽  
pp. 84-88 ◽  
Author(s):  
George A. Fraser
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Stress Disorder ◽  
Synthetic Cannabinoid ◽  
Treatment Resistant

scholarly journals Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder

2008 ◽  
Vol 25 (1) ◽  
pp. 69-71 ◽  
Author(s):  
Beth S. Gershuny ◽  
Lee Baer ◽  
Holly Parker ◽  
Emily L. Gentes ◽  
Alison L. Infield ◽  
...  
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Obsessive Compulsive Disorder ◽  
Stress Disorder ◽  
Treatment Resistant ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

Treatment-Resistant Posttraumatic Stress Disorder: Strategies for Intervention

CNS Spectrums ◽  
2004 ◽  
Vol 9 (10) ◽  
pp. 740-752 ◽  
Author(s):  
Mark B. Hamner ◽  
Sophie Robert ◽  
B. Christopher Frueh
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Atypical Antipsychotics ◽  
Therapeutic Response ◽  
Stress Disorder ◽  
Symptom Clusters ◽  
Mood Stabilizers ◽  
Treatment Resistant ◽  
First Line

AbstractThe mainstay of treatment for chronic posttraumatic stress disorder (PTSD) is a combination of psychotherapy and medication treatments. The first-line medications for PTSD are antidepressants, with two selective serotonin reuptake inhibitors (sertraline and paroxetine) currently Food and Drug Administration-indicated for PTSD. However, many patients do not have an adequate response to antidepressants, therefore, combinations with other antidepressants or with other classes of psychotropic medication are often utilized to enhance the therapeutic response. Other agents that have been used include mood stabilizers, antiadrenergics, anxiolytics, and atypical antipsychotics. The heterogeneity of symptom clusters in PTSD as well as the complex psychiatric comorbidities (eg, with depression or substance abuse) further support the notion that combinations of medications may be needed. To date, there is a paucity of data to support specific strategies for augmenting antidepressants in PTSD. This review will address representative existing studies and discuss several potential pharmacologic strategies for patients suffering from treatment refractory PTSD.

Open Study of Creatine Monohydrate in Treatment-Resistant Posttraumatic Stress Disorder

2006 ◽  
Vol 67 (05) ◽  
pp. 836-837 ◽  
Author(s):  
Daniela Amital ◽  
Tali Vishne ◽  
Suzana Roitman ◽  
Moshe Kotler ◽  
Joseph Levine
Keyword(s):  
Posttraumatic Stress Disorder ◽  
Posttraumatic Stress ◽  
Open Study ◽  
Stress Disorder ◽  
Creatine Monohydrate ◽  
Treatment Resistant
Sign in / Sign up

Export Citation Format

Share Document